A Single-center, Prospective, Non-comparative Clinical Trial of Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome

Status: Not yet recruiting

Phase of Trial: Phase III

Latest Information Update: 07 Jun 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

16 Mar 2022 Planned End Date changed from 1 Jan 2023 to 1 Jun 2024.
16 Mar 2022 Planned primary completion date changed from 1 Jan 2023 to 1 Jun 2023.
16 Mar 2022 Planned initiation date changed from 1 Jan 2022 to 1 Jun 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com